Table 4.
Odds Ratios and 95% confidence intervals for COVID-19 severity in cancer patients.
| OR* | 95% CI | |
|---|---|---|
| Sex | ||
| Male | 1.00 | Ref |
| Female | 0.59 | (0.25–1.40) |
| Age | ||
| ≤60 | 1.00 | Ref |
| >60 | 0.82 | (0.35–1.93) |
| SES | ||
| Low | 1.00 | Ref |
| Middle | N/A | N/A |
| High | 2.11 | (0.51–8.67) |
| Ethnicity | ||
| White | 1.00 | Ref |
| Black | 0.40 | (0.13–1.28) |
| Asian | 1.55 | (0.26–9.16) |
| Other | 0.52 | (0.06–4.57) |
| Number of comorbidities | ||
| 0 | 1.00 | Ref |
| 1 | 1.09 | (0.29–4.07) |
| 2 | 1.04 | (0.23–4.68) |
| 3+ | 1.26 | (0.29–5.41) |
| P for trend | 0.776 | |
| Smoking history | ||
| Never | 1.00 | Ref |
| Ever | 1.39 | (0.36–5.33) |
| Cancer type | ||
| Solid | 1.00 | Ref |
| Hematological | 3.14 | (0.70–14.03) |
| Treatment paradigm | ||
| No active treatment | 1.00 | Ref |
| Radical/curative | 2.76 | (0.34–22.16) |
| Palliative | 3.40 | (0.50–23.20) |
| Time since cancer diagnosis | ||
| ≤24 months | 1.00 | Ref |
| >24 months | 1.74 | (0.71–4.26) |
| Performance status | ||
| 0–2 | 1.00 | Ref |
| 3+ | 0.33 | (0.04–2.64) |
| Symptoms | ||
| Cough | 1.27 | (0.53–3.01) |
| Fever | 6.21 | (1.76–21.99) |
| Dyspnea | 2.60 | (1.00–6.76) |
| GI symptoms | 7.38 | (2.71–20.16) |
| Time between first symptom and diagnosis | ||
| <7 days | 1.00 | Ref |
| 7–14 days | 0.85 | (0.28–2.54) |
| >14 days | 1.02 | (0.26–4.02) |
| CRP (mg/L) | ||
| T1 (3–41) | 1.00 | Ref |
| T2 (42–117) | 1.95 | (0.19–20.25) |
| T3 (126–508) | 9.43 | (0.73–121.12) |
| Lymphocytes (×109) | ||
| ≤0.5 | 1.00 | Ref |
| 0.6–0.8 | 0.49 | (0.06–3.73) |
| 0.9–1.2 | 0.27 | (0.03–2.34) |
| >1.2 | 0.63 | (0.07–5.84) |
| Albumin (g/L) | ||
| T1 (20–32) | 1.00 | Ref |
| T2 (33–38) | 1.13 | (0.18–7.00) |
| T3 (39–57) | 0.07 | (0.01–0.96) |
*
Adjustment as defined by the DAG (Table A1).